

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/030,225		06/27/2002	Toshio Ota	084335-0153	9216
22428	7590	01/26/2004		EXAMINER	
FOLEY AN	ID LAR	DNER	PRIEBE, SCOTT DAVID		
SUITE 500 3000 K STREET NW				ART UNIT	PAPER NUMBER
WASHINGTON, DC 20007				1632	

DATE MAILED: 01/26/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
		OTA ET AL.					
Office Action Summary	10/030,225 Examiner	Art Unit					
• • • • • • • • • • • • • • • • • • •	Scott D. Priebe	1632					
The MAILING DATE of this communication a							
Period for Reply	·						
A SHORTENED STATUTORY PERIOD FOR REP THE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a re  - If NO period for reply is specified above, the maximum statutory perio  - Failure to reply within the set or extended period for reply will, by statu.  - Any reply received by the Office later than three months after the mail earned patent term adjustment. See 37 CFR 1.704(b).  Status	. 136(a). In no event, however, may a reply be to ply within the statutory minimum of thirty (30) dad will apply and will expire SIX (6) MONTHS froute, cause the application to become ABANDON	imely filed  ays will be considered timely.  In the mailing date of this communication.  ED (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on	<u></u> .						
2a) This action is <b>FINAL</b> . 2b) ⊠ Thi	s action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) ☐ Claim(s) 1-18 is/are pending in the application 4a) Of the above claim(s) is/are withdr 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-18 are subject to restriction and/o	awn from consideration.						
Application Papers							
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) according a deplicant may not request that any objection to the Replacement drawing sheet(s) including the correction.  The oath or declaration is objected to by the Examin 11).	ccepted or b) objected to by the e drawing(s) be held in abeyance. Section is required if the drawing(s) is o	ee 37 CFR 1.85(a). bjected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. §§ 119 and 120							
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> <li>13) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet.</li> <li>37 CFR 1.78.</li> <li>a) The translation of the foreign language provisional application has been received.</li> <li>14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.</li> </ul>							
Attachment(s)							
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO-1449) Paper No(s)</li> </ol>	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)					

Application/Control Number: 10/030,225

Art Unit: 1632

## **DETAILED ACTION**

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 4-10, drawn to polynucleotides encoding SEQ ID NO: 2, including probes, primers, anti-sense thereto, and first recited method of use thereof.

Group II, claim(s) 2, 3, 11, drawn to the polypeptide of SEQ ID NO: 2, and first recited method of using same to identify a receptor clone.

Group III, claim(s) 12, drawn to a gene encoding a receptor of the polypeptide of SEQ ID NO: 2.

Group IV, claim(s) 13, drawn to a receptor of the polypeptide of SEQ ID NO: 2.

Group V, claim(s) 14, drawn to the second recited method of using the polypeptide of SEQ ID NO: 2, in identifying a compound that inhibits binding of the polypeptide to its receptor.

Group VI, claim(s) 15, drawn to a compound that inhibits binding of the polypeptide of SEQ ID NO: 2 to its receptor.

Group VII, claim(s) 16-18, drawn to a non-human vertebrate having expression of the polypeptide of SEQ ID NO: 2 decreased.

Group VIII, claim(s) 16-18, drawn to a non-human vertebrate having expression of the polypeptide of SEQ ID NO: 2 increased.

The inventions listed as Groups I-VIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

With regard to the application of PCT Rule 13, 37 CFR 1.475 does not provide for multiple distinct products or multiple distinct methods of using a product. Consequently, Groups I, II, III,

Application/Control Number: 10/030,225

Art Unit: 1632

IV, VI, VII, and VIII cannot be said to share a special technical feature since the products (and methods for using same) are structurally and functionally different products, or biochemically and biologically different compounds. Group V is a different method of using the polypeptide of Group II than the method included in group II, involving different products, process steps, and aims.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Scott D. Priebe whose telephone number is (571) 272-0733. The examiner can normally be reached on M-F, 8:00-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy J. Nelson can be reached on (571) 272-0804. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Scott D. Priebe Primary Examiner

Art Unit 1632